Lexicon (LXRX) Q3 2023 Earnings Call Nov 2

Lexicon Pharmaceuticals (Nasdaq: LXRX) is set to release its financial results for the third quarter ended September 30, 2023, before the market opens on Thursday, November 2, 2023.

Following the earnings release, the biopharmaceutical company’s management team will host a conference call and live webcast to discuss the financial outcomes and provide a general business update. The event is scheduled for the same day, Thursday, November 2nd, at 8:00 a.m. Eastern Time.

Investors and the public can access the live webcast by visiting the “Events & Presentations” section under the “Investors” menu on Lexicon’s corporate website at www.lexpharma.com. For those who prefer to listen by phone, U.S. and Canadian participants can dial 877-407-0778, while international callers should use 201-689-8565. A replay of the webcast will be made available on the company’s website shortly after the conclusion of the live call.

Lexicon Pharmaceuticals, headquartered in The Woodlands, Texas, is a fully integrated biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for patients with serious diseases. The company’s key commercial product, Inpefa (sotagliflozin), was approved by the U.S. Food and Drug Administration (FDA) earlier this year for the reduction of risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adult patients with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. The upcoming earnings report will provide crucial insights into Inpefa’s initial commercial performance, as well as updates on Lexicon’s broader pipeline and financial outlook.

Analysts and investors will be closely watching for details on Inpefa sales, any advancements in its ongoing clinical programs, and the company’s overall financial health as it continues to execute its commercial strategy and invest in research and development.